文献速递骨软组织肉瘤与黑色素瘤消化系统肿瘤

伊马替尼辅助治疗局限性高危/中危GIST的最终分析

Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)☆.
PubMed 文献 · Ann Oncol · 2021-01-19

中位随访9.1年,伊马替尼失败无生存(IFFS)无显著差异,无复发生存(RFS)显著改善,总生存(OS)无显著差异;高危亚组中伊马替尼组长期IFFS和RFS有改善趋势。

要点

  • 2年辅助伊马替尼未显著改善IFFS(HR=0.87,P=0.31)。
  • 辅助伊马替尼显著改善RFS(HR=0.71,P=0.002)。
  • 高危亚组中10年IFFS和RFS伊马替尼组数值更高,但未报告统计检验。

核心结论

  • 中位随访9.1年,辅助伊马替尼2年组较观察组IFFS无显著差异,RFS显著改善,OS无显著差异。
  • 高危亚组中伊马替尼组10年IFFS和RFS数值上高于观察组,但未报告统计学显著性。

研究设计与样本

  • 随机、开放标签、多中心III期试验,在12个国家112家医院开展。
  • 伊马替尼400mg每日一次,持续2年;主要终点为IFFS,次要终点包括RFS、RFI、OS和毒性。
  • IFFS按4.3%显著性水平检验,其他终点按5%显著性水平检验。

主要发现

  • 中位随访9.1年,5年(10年)IFFS伊马替尼组87%(75%)vs 观察组83%(74%),HR=0.87,95.7%CI(0.65;1.15),P=0.31。
  • 5年RFS伊马替尼组70% vs 观察组63%,10年RFS 63% vs 61%,HR=0.71,95%CI(0.57;0.89),P=0.002。
  • 5年OS伊马替尼组93% vs 观察组92%,10年OS 80% vs 78%,HR=0.88,95%CI(0.65;1.21),P=0.43。
  • 局部病理高危GIST患者526例中,10年IFFS伊马替尼组69% vs 观察组61%,10年RFS 48% vs 43%。

关键数值与推荐

  • 原文未报告RFI和毒性的具体数值。

临床怎么用

  • 对于局限性高危GIST术后患者,2年辅助伊马替尼可改善RFS,但IFFS和OS未显示显著获益。
  • 高危亚组中10年IFFS和RFS的数值改善趋势需结合其他试验(如 Scandinavian/German 试验)综合解读。

局限性

  • IFFS作为替代终点的有效性未经验证。
  • 高危亚组分析未报告统计学检验,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2004, we started an intergroup randomized trial of adjuvant imatinib versus no further therapy after R0-R1 surgery in localized, high/intermediate-risk gastrointestinal stromal tumors (GIST) patients. Interim analysis results were published in 2015 upon recommendation from an independent data review committee. We report the final outcome of the study. PATIENTS AND METHODS: This was a randomized, open-label, multicenter phase III trial carried out at 112 hospitals in 12 countries. Patients were randomized to 2 years of imatinib, 400 mg daily, or no further therapy after surgery. The primary endpoint was imatinib failure-free survival (IFFS), while relapse-free survival (RFS), relapse-free interval (RFI), overall survival (OS) and toxicity were secondary endpoints. Adjusting for the interim analyses, results on IFFS were assessed on a 4.3% significance level; for the other endpoints, 5% was used. RESULTS: Nine hundred and eight patients were randomized between January 2005 and October 2008: 454 to imatinib and 454 to observation; 835 patients were eligible. With a median follow-up of 9.1 years, 5 (10)-year IFFS was 87% (75%) in the imatinib arm versus 83% (74%) in the control arm [hazard ratio (HR) = 0.87, 95.7% confidence interval (CI) (0.65; 1.15), P = 0.31]; RFS was 70% versus 63% at 5 years and 63% versus 61% at 10 years, [HR = 0.71, 95% CI (0.57; 0.89), P = 0.002]; OS was 93% versus 92% at 5 years and 80% versus 78% at 10 years [HR = 0.88, 95% CI (0.65; 1.21), P = 0.43]. Among 526 patients with high-risk GIST by local pathology, 10-year IFFS and RFS were 69% versus 61%, and 48% versus 43%, respectively. CONCLUSIONS: With 9.1 years of follow-up, a trend toward better long-term IFFS in imatinib-treated patients was observed in the high-risk subgroup. Although the difference was not statistically significant and the surrogacy value of such an endpoint is not validated, this may be seen as supporting the results reported by the Scandinavian/German trial, showing a sustained small but significant long-term OS benefit in high-risk GIST patients treated with 3 years of adjuvant imatinib.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Casali PG, Le Cesne A, Velasco AP, et al. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)☆. Ann Oncol. 2021. PMID: 33482247. doi:10.1016/j.annonc.2021.01.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。